efectos secundarios del glp 1 adversos gastrointestinales de viejos y nuevos antidiabéticos: ¿cómo los enfrentamos en la vida real? VIDEO 4/5 🎥 Los efectos

The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in late 2024, which ended the shortage-list justification that most large-scale compounding relied on

Because obesity is closely related to PCOS, it is not surprising that IF could provide benefits by reducing insulin resistance and easing hyperandrogenemia (57), because it may also affect chemotherapy

This announcement is limited to operational and documentation changes intended to support clean recordkeeping and repeatable laboratory workflows, and it does not introduce clinical, diagnostic, therapeutic, or human-use positioning

Temporary water retention is occasionally reported, but it is usually not a significant concern